{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:10:33Z","timestamp":1778620233563,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002338","name":"Ministry of Education of the People&apos;s Republic of China","doi-asserted-by":"publisher","award":["XNYKDXCXZX-2024-13"],"award-info":[{"award-number":["XNYKDXCXZX-2024-13"]}],"id":[{"id":"10.13039\/501100002338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82030007"],"award-info":[{"award-number":["82030007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U23A20398"],"award-info":[{"award-number":["U23A20398"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eprac.2025.05.001","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:27:33Z","timestamp":1746725253000},"page":"1061-1070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Life-Saving Drug or Potential Threat? The Role of Mineralocorticoid Receptor Antagonists in Myocardial Infarction: A Meta-Analysis"],"prefix":"10.1016","volume":"31","author":[{"given":"Xiangfeng","family":"Guan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2025.05.001_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jacc.2008.08.067","article-title":"Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction","volume":"53","author":"Ezekowitz","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"9852","key":"10.1016\/j.eprac.2025.05.001_bib2","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(12)61223-9","article-title":"Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial","volume":"380","author":"Sabate","year":"2012","journal-title":"Lancet"},{"issue":"9792","key":"10.1016\/j.eprac.2025.05.001_bib3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(11)60876-3","article-title":"Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial","volume":"378","author":"Montalescot","year":"2011","journal-title":"Lancet"},{"issue":"2 Pt 2","key":"10.1016\/j.eprac.2025.05.001_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.37.2.787","article-title":"Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury","volume":"37","author":"Fiebeler","year":"2001","journal-title":"Hypertension"},{"issue":"20","key":"10.1016\/j.eprac.2025.05.001_bib5","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.eprac.2025.05.001_bib6","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","article-title":"High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction","volume":"114","author":"Beygui","year":"2006","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.eprac.2025.05.001_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049036","article-title":"The aldosterone-mineralocorticoid receptor pathway exerts anti-inflammatory effects in endotoxin-induced uveitis","volume":"7","author":"Bousquet","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.eprac.2025.05.001_bib8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","article-title":"Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy","volume":"8","author":"Roscioni","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1016\/j.eprac.2025.05.001_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10741-005-2351-3","article-title":"Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure","volume":"10","author":"Zannad","year":"2005","journal-title":"Heart Fail Rev"},{"issue":"5 Suppl","key":"10.1016\/j.eprac.2025.05.001_bib10","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1067\/mhj.2002.129969","article-title":"Aldosterone: cardiovascular assault","volume":"144","author":"Struthers","year":"2002","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.eprac.2025.05.001_bib11","doi-asserted-by":"crossref","first-page":"3A","DOI":"10.1016\/0002-9149(93)90238-8","article-title":"Aldosterone and antialdosterone therapy in congestive heart failure","volume":"71","author":"Weber","year":"1993","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.eprac.2025.05.001_bib12","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"18","key":"10.1016\/j.eprac.2025.05.001_bib13","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.eprac.2025.05.001_bib14","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.eprac.2025.05.001_bib15","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized double-blind reminder study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.eprac.2025.05.001_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1056\/NEJMoa2405923","article-title":"Routine spironolactone in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.eprac.2025.05.001_bib17","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.eprac.2025.05.001_bib18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2017.09.010","article-title":"Mineralocorticoid receptor antagonists in patients with acute myocardial infarction - a systematic review and meta-analysis of randomized trials","volume":"195","author":"Bossard","year":"2018","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.eprac.2025.05.001_bib19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2018.0850","article-title":"Aldosterone antagonist therapy and mortality in patients with ST-segment elevation myocardial infarction without heart failure: a systematic review and meta-analysis","volume":"178","author":"Dahal","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"51","key":"10.1016\/j.eprac.2025.05.001_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013690","article-title":"Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: a meta-analysis of randomized controlled trials","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.eprac.2025.05.001_bib21","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2025.05.001_bib22","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2025.05.001_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.eprac.2025.05.001_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"issue":"7414","key":"10.1016\/j.eprac.2025.05.001_bib25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.eprac.2025.05.001_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","article-title":"Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction","volume":"141","author":"Modena","year":"2001","journal-title":"Am Heart J"},{"issue":"2-3","key":"10.1016\/j.eprac.2025.05.001_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0167-5273(00)00425-3","article-title":"The combination ace-inhibitors plus canreonate in patients with anterior myocardial infarction: safety and tolerability study","volume":"77","author":"Di Pasquale","year":"2001","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.eprac.2025.05.001_bib28","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ahj.2005.03.032","article-title":"Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction","volume":"150","author":"Di Pasquale","year":"2005","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.eprac.2025.05.001_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/00365510902802278","article-title":"Effects of aldosterone blockade on left ventricular function and clinical status during acute myocardial infarction","volume":"69","author":"Uzunhasan","year":"2009","journal-title":"Scand J Clin Lab Invest"},{"issue":"6","key":"10.1016\/j.eprac.2025.05.001_bib30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ahj.2009.04.001","article-title":"Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?","volume":"157","author":"Weir","year":"2009","journal-title":"Am Heart J"},{"issue":"8","key":"10.1016\/j.eprac.2025.05.001_bib31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCA.0b013e32833fd243","article-title":"The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction: a randomized follow-up study","volume":"21","author":"Kayrak","year":"2010","journal-title":"Coron Artery Dis"},{"issue":"1","key":"10.1016\/j.eprac.2025.05.001_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5847\/wjem.j.issn.1920-8642.2013.01.009","article-title":"Effect of spironolactone on cardiac remodeling after acute myocardial infarction","volume":"4","author":"Wu","year":"2013","journal-title":"World J Emerg Med"},{"key":"10.1016\/j.eprac.2025.05.001_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2019.02.005","article-title":"Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: the MINIMIZE STEMI trial","volume":"211","author":"Bulluck","year":"2019","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.eprac.2025.05.001_bib34","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.eprac.2025.05.001_bib35","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/HYPERTENSIONAHA.109.136242","article-title":"Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction","volume":"54","author":"Mihailidou","year":"2009","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.eprac.2025.05.001_bib36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","article-title":"Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Li","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"7","key":"10.1016\/j.eprac.2025.05.001_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/jmcc.1994.1098","article-title":"Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone","volume":"26","author":"Brilla","year":"1994","journal-title":"J Mol Cell Cardiol"},{"issue":"22","key":"10.1016\/j.eprac.2025.05.001_bib38","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES)","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.eprac.2025.05.001_bib39","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/ejhf.2952","article-title":"Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: a subgroups analysis from the EMPHASIS-HF trial","volume":"25","author":"Monzo","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.eprac.2025.05.001_bib40","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3317\/jraas.2003.025","article-title":"Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease","volume":"4","author":"Pitt","year":"2003","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"6","key":"10.1016\/j.eprac.2025.05.001_bib41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","article-title":"Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure","volume":"101","author":"Farquharson","year":"2000","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.eprac.2025.05.001_bib42","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004373","article-title":"Invasive assessment of the coronary microcirculation in reperfused ST-segment-elevation myocardial infarction patients: where do we stand?","volume":"10","author":"Bulluck","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.eprac.2025.05.001_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jama.2011.1967","article-title":"Serum potassium levels and mortality in acute myocardial infarction","volume":"307","author":"Goyal","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eprac.2025.05.001_bib44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.eprac.2025.05.001_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.eprac.2025.05.001_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5455\/medarh.2023.77.105-111","article-title":"The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF","volume":"77","author":"Naser","year":"2023","journal-title":"Med Arch"},{"key":"10.1016\/j.eprac.2025.05.001_bib47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejim.2021.12.027","article-title":"Real world comparison of spironolactone and eplerenone in patients with heart failure","volume":"97","author":"Pardo-Mart\u00ednez","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.05.001_bib48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ejhf.31","article-title":"Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure","volume":"16","author":"Iqbal","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.eprac.2025.05.001_bib49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J"},{"issue":"14","key":"10.1016\/j.eprac.2025.05.001_bib50","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.05.079","article-title":"Patiromer facilitates angiotensin inhibitor and mineralocorticoid antagonist therapies in patients with heart failure and hyperkalemia","volume":"84","author":"Pitt","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25001430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25001430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:15:18Z","timestamp":1778616918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25001430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1530891X25001430"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.05.001","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Life-Saving Drug or Potential Threat? The Role of Mineralocorticoid Receptor Antagonists in Myocardial Infarction: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}